Early and locally advanced breast cancers are invasive breast cancers. However, they have not spread beyond the breast and nearby lymph nodes to other parts of the body they are not metastatic. Early breast cancer is contained in the breast. Or, it has only spread to the lymph nodes in the underarm area.
Management of Early-Stage HER2-Positive Breast Cancer
Management of Early-Stage HER2-Positive Breast Cancer | Cancer Network
October 10, , by NCI Staff. New study results show that for women with early-stage breast cancer, having only a sentinel lymph node biopsy after lumpectomy, rather than a more aggressive biopsy procedure, did not decrease survival. Long-term results from a large clinical trial confirm that, for some women with early-stage breast cancer who have lumpectomy as their surgical treatment, a less extensive lymph node biopsy approach is sufficient. The trial showed that women with early-stage breast cancer who have cancer cells in one or two sentinel lymph nodes can skip axillary lymph node dissection ALND after breast-conserving surgery without affecting their long-term survival. The findings are important for patients because ALND can cause chronic side effects such as numbness, decreased range of motion in the upper body, and lymphedema , said Armando Giuliano, M. The axillary lymph nodes run from the breast tissue into the armpit.
Meta-Analysis Finds Benefits of Adjuvant Bisphosphonates for Postmenopausal Breast Cancer
Steady rates of recurrence in women with estrogen receptor-positive disease could influence decisions about long-term therapy. Even 20 years after a diagnosis, women with a type of breast cancer fueled by estrogen still face a substantial risk of cancer returning or spreading, according to a new analysis from an international team of investigators published in the New England Journal of Medicine. Standard treatment for estrogen receptor-positive, or ER-positive, breast cancer includes five years of the endocrine-based treatments tamoxifen or aromatase inhibitors, both of which are taken daily as a pill. The patients all received endocrine therapy for five years and were free of cancer when they stopped therapy. Over the next 15 years, however, a steady number of these women saw their cancer spread throughout the body, as late as 20 years after the initial diagnosis.
The "late recurrence" or relapse of breast cancer refers to cancers that come back after five years, but may not return for 10 years, 20 years, or even more. For people who have estrogen receptor-positive tumors, the cancer is actually more likely to recur after five years than in the first five years. An awareness of the risk of late recurrence is important for a number of reasons. People are often shocked to learn that their breast cancer has come back after say, 15 years, and loved ones who don't understand this risk are often less likely to be supportive as you cope with the fear of recurrence. While chemotherapy has little effect on the risk of late recurrence hormonal therapy does, and estimating this risk may help determine who should receive extended hormonal therapy beyond five years.